PT  - JOURNAL ARTICLE
AU  - Bello-Chavolla, Omar Yaxmehen
AU  - Bahena-López, Jessica Paola
AU  - Antonio-Villa, Neftali Eduardo
AU  - Vargas-Vázquez, Arsenio
AU  - González-Díaz, Armando
AU  - Márquez-Salinas, Alejandro
AU  - Fermín-Martínez, Carlos A.
AU  - Naveja, J. Jesús
AU  - Aguilar-Salinas, Carlos A.
TI  - Predicting mortality attributable to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico
AID  - 10.1101/2020.04.20.20072223
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.20.20072223
4099  - http://medrxiv.org/content/early/2020/04/24/2020.04.20.20072223.short
4100  - http://medrxiv.org/content/early/2020/04/24/2020.04.20.20072223.full
AB  - BACKGROUND AND AIMS The SARS-CoV-2 outbreak has posed a challenge to the healthcare systems due to high complications rates observed in patients with cardiometabolic diseases, such as diabetes and obesity. Despite the high prevalence of these conditions, a mechanistic association of its interactions in COVID-19 remain unclear. Here, we identify risk factors and propose a clinical score to predict 30-day lethality in COVID-19 cases, including specific factors for diabetes and obesity and its role in improving risk prediction.METHODS We obtained data of suspected, confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of Mexican Ministry of Health. We investigated specific risk factors associated to SARS-CoV-2 positivity and mortality due to COVID-19. Additionally, we explored the impact of diabetes and obesity on COVID-19 related outcomes and their interaction with other comorbidities in modifying COVID-19 related lethality. Finally, we built our clinical score to predict 30-day lethality using the previously identified risk factors.RESULTS Among 49,570 evaluated subjects (at April 19th, 2020), we observed an increased risk of SARS-CoV-2 positivity (n=8,261) in those with diabetes, obesity, male subjects and in patients with diabetes and age <40 years (early-onset). Risk factors for increased lethality in COVID-19 includes early-onset diabetes obesity, chronic obstructive pulmonary disease, advanced age, immunosuppression, and chronic kidney disease; we also found that obesity mediates 47.8% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU admission and intubation. Our predictive score for COVID-19 lethality included age ≥ 65 years, diabetes, diabetes & age <40 years, obesity, age <40 years, CKD, pregnancy and immunosuppression and a categorization of low-risk, mild-risk, moderate-risk, high-risk and very high-risk significantly discriminates lethal from non-lethal COVID-19 cases (c- statistic=0.837).CONCLUSIONS Here, we propose a mechanistic approach to evaluate risk for complication and lethality attributable to COVID-19 in patients with obesity and diabetes patients in a country with high susceptibility. Furthermore, our novel score offers a clinical tool for quick determination of high-risk susceptibility patients in a first contact scenario.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data sources and R code are available for reproducibility of results at https://github.com/oyaxbell/covid_diabetesmx. https://github.com/oyaxbell/covid_diabetesmx